AI

Traditional drug discovery has operated for decades under an economics model that would be considered untenable in almost any other industry. Pipelines crowded with candidates that fail in late-stage trials, targets pursued on biological intuition rather than rigorous evidence, and chemistry processes that consume years before a molecule reaches its first human test—all sustained by

Drug discovery has historically been an exercise in expensive attrition. The conventional model—identify a disease target, screen compounds, optimise leads, test preclinically, and hope clinical trials vindicate the original hypothesis—is sequential, slow, and brutally uncertain. Candidates fail at every stage, often because the biological target was poorly validated long before a molecule was synthesised. The